Ustekinumab biosimilar is under clinical development by NeuClone and currently in Phase I for Psoriatic Arthritis. According to GlobalData, Phase I drugs for Psoriatic Arthritis have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ustekinumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ustekinumab biosimilar overview
Ustekinumab biosimilar is under development for the treatment of active psoriatic arthritis, moderate to severely active Crohn's disease, moderate to severe plaque psoriasis and ulcerative colitis. It is administered through the subcutaneous route. The drug candidate acts by targeting interleukin 12 subunit beta and interleukin 23 subunit alpha. It is developed based on NeuMAX technology.
NeuClone is a clinical-stage biopharmaceutical company exclusively developing and commercializing high-quality biosimilar products. They provide services like biosimilars, monoclonal antibodies, biosimilar antibody development in CHO cells, therapeutic antibodies, and biologics. The company is headquartered in Sydney, New South Wales.
For a complete picture of Ustekinumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.